Atea Pharmaceuticals

Roche and Atea Pharmaceuticals Link Up To Co-Develop Remdesivir Rival Drug For COVID-19
Clinical News

Roche and Atea Pharmaceuticals Link Up To Co-Develop Remdesivir Rival Drug For COVID-19

The two companies will jointly develop, manufacture and distribute AT-527, Atea’s investigational oral antiviral for the potential treatment of COVID-19. According to Roche, AT-527 blocks the viral RNA polymerase enzyme…
زر الذهاب إلى الأعلى